Learn how T-cell and B-cell sequencing can be translated into meaningful biological and clinical insights.
Archives: News & Updates
Adaptive Biotechnologies announces two immune receptor licensing agreements with Pfizer
Learn how Pfizer Inc. (NYSE: PFE) is leveraging Adaptive’s proprietary TCR discovery capabilities and large-scale immune receptor antigen mapping data.
The power of antigen-specific TCR signatures in developing next-gen immunotherapies
Discover the diverse applications of TCR deep sequencing and T-cell specificity to accelerate the development of cancer medicines.